HOME
PRODUCTS
COMPANY
CONTACT
FAQ
Research
Dictionary
Pharma
Sign Up
FREE
or
Login
Username:
Password:
Remember login
Login
Send password reminder...
Takahiro Yamazaki Selected Research
Takahiro Yamazaki Research Topics
Disease
48
Neoplasms (Cancer)
01/2021 - 01/2003
8
Breast Neoplasms (Breast Cancer)
01/2021 - 11/2014
6
Carcinoma (Carcinomatosis)
01/2021 - 06/2013
4
Inflammation (Inflammations)
01/2022 - 01/2020
4
Melanoma (Melanoma, Malignant)
10/2019 - 11/2015
2
Dementia (Dementias)
05/2022 - 11/2020
2
Disease Progression
01/2021 - 01/2020
2
Triple Negative Breast Neoplasms
01/2021 - 01/2021
2
Bites and Stings (Sting)
10/2020 - 01/2019
2
Hepatocellular Carcinoma (Hepatoma)
04/2020 - 07/2012
2
Stroke (Strokes)
01/2020 - 02/2014
2
Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung)
04/2019 - 01/2019
2
Leukemia
01/2017 - 05/2012
2
Neoplasm Metastasis (Metastasis)
03/2016 - 01/2003
1
Alzheimer Disease (Alzheimer's Disease)
05/2022
1
Dystonia (Limb Dystonia)
05/2022
1
Mitochondrial Diseases (Mitochondrial Disease)
01/2022
1
Wrist Fractures
11/2021
1
Hyperglycemia
01/2021
1
Metabolic Syndrome (Dysmetabolic Syndrome X)
01/2021
1
Cognitive Dysfunction
11/2020
1
Asthenopia (Eyestrain)
07/2020
1
Insulin Resistance
01/2020
1
Carcinogenesis
01/2020
1
Ischemia
01/2020
1
Cutaneous T-Cell Lymphoma (Lymphoma, T Cell, Cutaneous)
01/2019
1
Polyploidy
11/2017
Drug/Important Bio-Agent (IBA)
9
Anthracyclines
IBA
06/2016 - 07/2012
7
Immune Checkpoint Inhibitors
IBA
01/2021 - 01/2016
5
Peptides (Polypeptides)
IBA
01/2021 - 01/2016
5
Antineoplastic Agents (Antineoplastics)
IBA
01/2021 - 06/2013
5
Interferon Type I
IBA
10/2020 - 11/2014
4
Adenosine Triphosphate (ATP)
IBA
01/2021 - 04/2013
4
Hormones (Hormone)
IBA
01/2021 - 01/2020
4
Biomarkers (Surrogate Marker)
IBA
04/2020 - 01/2019
4
Oxaliplatin (Eloxatin)
FDA Link
Generic
06/2016 - 07/2012
3
Cytostatic Agents
IBA
01/2021 - 01/2019
3
Cytokines
IBA
01/2021 - 05/2012
3
Carcinogens
IBA
01/2021 - 09/2012
3
Phenobarbital (Luminal)
FDA Link
01/2021 - 01/2020
3
Antigens
IBA
01/2020 - 01/2016
3
Cyclophosphamide (Cytoxan)
FDA Link
Generic
10/2016 - 11/2013
3
Interferons
IBA
02/2016 - 08/2015
2
Retinaldehyde (Retinal)
IBA
01/2022 - 01/2020
2
Food Ingredients
IBA
11/2020 - 01/2020
2
Indicators and Reagents (Reagents)
IBA
07/2020 - 05/2012
2
theasinensin A
IBA
01/2020 - 01/2019
2
Crizotinib
IBA
04/2019 - 01/2019
2
Caspase 3 (Caspase-3)
IBA
01/2019 - 06/2016
2
Antibodies
IBA
01/2019 - 11/2015
2
HMGB1 Protein (HMG1)
IBA
01/2019 - 06/2016
2
Calreticulin
IBA
01/2019 - 09/2012
2
Vaccines
IBA
01/2019 - 07/2012
2
DNA (Deoxyribonucleic Acid)
IBA
01/2019 - 09/2012
2
Chemokines
IBA
03/2016 - 09/2015
2
Chemokine Receptors
IBA
03/2016 - 09/2015
2
Anti-Bacterial Agents (Antibiotics)
IBA
11/2015 - 11/2013
2
Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)
IBA
06/2013 - 01/2008
1
brexpiprazole
IBA
05/2022
1
Quetiapine Fumarate (Seroquel)
FDA Link
05/2022
1
Interleukin-10 (Interleukin 10)
IBA
01/2022
1
Lipopolysaccharides
IBA
01/2022
1
Reactive Oxygen Species (Oxygen Radicals)
IBA
01/2022
1
Elements
IBA
11/2021
1
Estrogen Receptors
IBA
01/2021
1
LTX-315
IBA
01/2021
1
palbociclib
IBA
01/2021
1
Epitopes
IBA
01/2021
1
Histocompatibility Antigens Class II
IBA
01/2021
1
Apolipoproteins
IBA
01/2021
1
Therapeutic Uses
IBA
01/2021
1
Cyclin-Dependent Kinase 4
IBA
01/2021
1
Death Domain Receptors
IBA
01/2021
1
Acids
IBA
11/2020
1
Mitochondrial DNA (mtDNA)
IBA
10/2020
1
Triglycerides (Triacylglycerol)
IBA
04/2020
1
Inflammasomes
IBA
01/2020
1
Uric Acid (Urate)
IBA
01/2020
1
Niacinamide (Nicotinamide)
FDA Link
Generic
01/2020
1
anthracene
IBA
01/2020
1
diphosphoric acid (pyrophosphoric acid)
IBA
01/2020
1
Platinum
IBA
01/2020
1
Medroxyprogesterone Acetate (Depo-Provera)
FDA Link
Generic
01/2020
1
Nitric Oxide Synthase (NO Synthase)
IBA
10/2019
1
Monoclonal Antibodies
IBA
10/2019
1
Caspases
IBA
01/2019
1
Enzymes
IBA
01/2019
1
Blocking Antibodies
IBA
01/2019
1
LTX-401
IBA
01/2019
1
Cisplatin (Platino)
FDA Link
Generic
01/2019
1
Methoxsalen (Oxsoralen)
FDA Link
01/2019
1
TNF Receptor-Associated Factor 1
IBA
01/2018
1
Type II Tumor Necrosis Factor Receptors
IBA
01/2018
1
Histocompatibility Antigens Class I
IBA
11/2017
Therapy/Procedure
17
Therapeutics
01/2021 - 04/2013
10
Immunotherapy
01/2021 - 05/2012
9
Radiotherapy
01/2021 - 11/2017
9
Drug Therapy (Chemotherapy)
11/2020 - 10/2010
1
Injections
01/2019
1
Photopheresis
01/2019